Loading
A phase 2 trial of pembrolizumab and olaparib in lung cancer, run by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, now recruiting.
Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) is a phase 2, interventional study registered as NCT05623319 by Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, with a registry enrolment figure of 60 participants, started 2023-03-27 and due to reach its primary completion in 2027-07. Interventions recorded: Pembrolizumab/Olaparib. Conditions listed: SCLC,Extensive Stage. Primary outcome: Progression free survival (PFS). Lung eligibility wording from the registry: "Cytologically/histologically confirmed diagnosis of SCLC per the Veterans Administration Lung Study Group (VALG) staging system will be enrolled in this study". Sites: Italy. No results are recorded here; the registry entry is the source.
Shares PARP inhibitors, Olaparib, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Pembrolizumab, Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.
Shares PARP inhibitors, Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Lung cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag lung-deep-dive.